Top 10 search results from SERP

# pleural mesothelioma stages

Words or phrase for the review: «pleural mesothelioma stages»

Malignant Pleural Mesothelioma » Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript. Ascopubs.org

Mesothelioma: A Review » Mesothelioma is an insidious disease with long latency after asbestos exposure. New cases are continually diagnosed, although levels are declining with recognition of the asbestos risk and efforts to remove asbestos from the workplace. Treatment for early… Ncbi.nlm.nih.gov

Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review » Thoracic Cancer is an international oncology journal publishing basic, translational and applied clinical research in lung, esophageal, mediastinal & breast cancer. Onlinelibrary.wiley.com

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma » There is no accepted second-line therapy for patients with advanced malignant pleural mesothelioma (MPM), whose disease has progressed after first-line chemotherapy. The multitargeted tyrosine kinase inhibitor sunitinib malate targets several pathways overexpressed in mesothelioma. This phase II study assessed objective response to sunitinib and correlative biomarkers in patients with progressive pretreated MPM. Jto.org

Cookies

We may use cookies to offer you a better browsing experience, analyze site traffic, personalize content, and serve targeted advertisements. If you continue to use this site, you consent to our use of cookies.

Terms & Privacy

The information forward from this site may be provided by third parties. We will not be responsible with outside links, contents from source of information, methods of using, using or consequence of contents with users. All direct or indirect risk related to use of this site is borne entirely by you, the user.

We use advertising companies as Google AdSense, to serve ads when you visit our website. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and to know your choices about not having this information used by these companies, see https://policies.google.com/technologies/ads.

FB Home